Fertility PreservationFERT-ISSUESNCT07312058
Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology
An observational study of Fertility Preservation and Cancer Remission, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity. Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment. Read more about this study
- Who is it for?
- Ages 18 to 47 years
- Conditions the study is for
- Fertility Preservation, Cancer Remission, Reproductive Outcomes
- How many people
- 102 participants
- Where
- 1 siteFrance
- Study dates
- 17 Dec 2025to Jan 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 47 years
- All sexes
- No healthy volunteers
- Adult
Study population: Patients are recruited during follow-up consultations as part of the establishment of a fertility observatory within the Department of Medicine and Reproductive Biology at CHU Amiens Picardie
Who may be able to join
- Women
- Aged between 18 and 47 years
- Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment
- Having undergone a medical fertility preservation consultation
- Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine
- Currently in remission
- Having expressed non-opposition to participation in the study
Who cannot join
- Absence of remission
- Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)
- Decline to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Amiens Picardie
Amiens
Rosalie Cabry, Pr, Cabry.Rosalie@chu-amiens.fr
About this study
Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.
Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.
Read more
However, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.
This project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.
This work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).
Its objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.
This work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.
- Conditions
- Fertility Preservation, Cancer Remission, Reproductive Outcomes, Reproductive Health, Oncology, Fertility Counseling
- Keywords
- Fertility preservation, Cancer remission, Reproductive outcomes, Reproductive health, Oncology, Fertility counseling, Assisted reproductive technology, Psychological impact, Fertility observatory, Patient follow-up, Female cancer survivors, Fertility preservation techniques, Live birth rate
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of an identifiable reproductive outcome
Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project
Measured: 1 year
Secondary outcomes (11)
Type of fertility preservation method performed
Measured: 1 year
Time interval (in months) between diagnosis and fertility preservation
Measured: 1 year
Correlation between Age and occurance of an identifiable reproductive outcome
Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project
Measured: 1 year
Time interval (in months) between fertility preservation and initiation of potentially gonadotoxic treatment
Measured: 1 year
Number of type of cancer associated with identifiable reproductive outcome
Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project
Measured: 1 year
Correlation between type of treatment and occurence of an identifiable reproductive outcome
Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project
Measured: 1 year
Correlation between family status and occurence of an identifiable reproductive outcome
Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project
Measured: 1 year
Time interval (in months) between completion of treatment and pregnancy attempt (spontaneous or medically assisted)
Measured: 1 year
Actual utilization rate of preserved material
Measured: 1 year
Success rate of reuse attempts
Measured: 1 year
Proportion of patients who ultimately did not pursue parenthood
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2025
- Study start17 Dec 2025 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fertility PreservationStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 102 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07312058
- Sponsor's protocol ID
- PI2025_843_0156
- Acronym
- FERT-ISSUES
- Status last verified
- Jan 2026
- First submitted
- 17 Nov 2025
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology
- ClinicalTrials.gov ID
- NCT07312058
- Acronym / sponsor ID
- FERT-ISSUES / PI2025_843_0156
- Conditions
- Fertility Preservation, Cancer Remission, Reproductive Outcomes, Reproductive Health, Oncology, Fertility Counseling
- Keywords
- Fertility preservation, Cancer remission, Reproductive outcomes, Reproductive health, Oncology, Fertility counseling, Assisted reproductive technology, Psychological impact
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 102 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 17 Dec 2025 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 31 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.
Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.
However, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.
This project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.
This work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).
Its objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.
This work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 to 47 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients are recruited during follow-up consultations as part of the establishment of a fertility observatory within the Department of Medicine and Reproductive Biology at CHU Amiens Picardie
Key inclusion criteria (7 listed)
- Women
- Aged between 18 and 47 years
- Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment
- Having undergone a medical fertility preservation consultation
- Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine
Key exclusion criteria (3 listed)
- Absence of remission
- Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)
- Decline to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Occurrence of an identifiable reproductive outcome
Time frame: 1 year
Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project
11 secondary outcomes
Type of fertility preservation method performed
Time frame: 1 year
Time interval (in months) between diagnosis and fertility preservation
Time frame: 1 year
Correlation between Age and occurance of an identifiable reproductive outcome
Time frame: 1 year
Time interval (in months) between fertility preservation and initiation of potentially gonadotoxic treatment
Time frame: 1 year
Number of type of cancer associated with identifiable reproductive outcome
Time frame: 1 year
Correlation between type of treatment and occurence of an identifiable reproductive outcome
Time frame: 1 year
Correlation between family status and occurence of an identifiable reproductive outcome
Time frame: 1 year
Time interval (in months) between completion of treatment and pregnancy attempt (spontaneous or medically assisted)
Time frame: 1 year
Actual utilization rate of preserved material
Time frame: 1 year
Success rate of reuse attempts
Time frame: 1 year
Proportion of patients who ultimately did not pursue parenthood
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Fertility Preservation
Active, not recruiting
Ovarian Tissue Cryopreservation in Children
Cancer
Not yet recruitingObservational study
Perceptions and Acceptance of Grafting of Cryopreserved Testicular Tissue
Fertility, Testicular Tissue Cryopreserved
RecruitingObservational study
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
Turner Syndrome, Post-menarcheal Adolescents
RecruitingObservational study
Follicular Flushing Versus Direct Aspiration in Transabdominal Oocyte Retrieval
Fertility Preservation
Recruiting
Investigating the Efficacy of a Paediatric Fertility Preservation Decision Aid in Parents and Adolescents and Young Adults (CAYA) Cancer Survivors
Unmet Fertility Information Needs
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fertility Preservation and Cancer Remission, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact CABRY-GOUBET Rosalie, Pr (33+3 22 08 80 00, cabry.rosalie@chu-amiens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of an identifiable reproductive outcome (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.